PDS Biotechnology
PDSB
PDS Biotechnology (PDSB) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.18
- EPS estimate
- −$0.13
- EPS surprise
- −38.46%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 13, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | −$0.13 | −$0.18 | −38.46% | $0.00 | SEC |
| Q1 2026 | May 13, 2026 | −$0.14 | −$0.13 | +7.14% | $0.00 | SEC |
| Q4 2025 | Mar 30, 2026 | −$0.20 | −$0.13 | +35.00% | $0.00 | SEC |
| Q3 2025 | Nov 13, 2025 | −$0.20 | −$0.19 | +3.41% | $0.00 | SEC |
| Q2 2025 | Aug 13, 2025 | −$0.23 | −$0.21 | +9.99% | $0.00 | SEC |
| Q1 2025 | May 14, 2025 | −$0.25 | −$0.21 | +14.88% | $0.00 | SEC |
| Q4 2024 | Mar 27, 2025 | −$0.28 | −$0.21 | +24.11% | $0.00 | SEC |
| Q3 2024 | Nov 14, 2024 | −$0.30 | −$0.29 | +2.26% | $0.00 | SEC |
| Q2 2024 | Aug 13, 2024 | −$0.33 | −$0.23 | +29.60% | $0.00 | SEC |
| Q1 2024 | May 15, 2024 | −$0.37 | −$0.30 | +18.19% | $0.00 | SEC |
| Q4 2023 | Mar 27, 2024 | −$0.44 | −$0.35 | +20.20% | $0.00 | SEC |
| Q3 2023 | Nov 14, 2023 | −$0.45 | −$0.35 | +21.47% | $0.00 | SEC |
| Q2 2023 | Aug 14, 2023 | −$0.35 | −$0.37 | −6.60% | $0.00 | SEC |
| Q1 2023 | May 15, 2023 | −$0.30 | −$0.32 | −6.67% | $0.00 | SEC |
| Q4 2022 | Mar 28, 2023 | −$0.29 | −$0.65 | −126.40% | $0.00 | SEC |
| Q3 2022 | Nov 14, 2022 | −$0.28 | −$0.26 | +7.60% | $0.00 | SEC |
| Q2 2022 | Aug 8, 2022 | −$0.28 | −$0.20 | +29.00% | $0.00 | SEC |
| Q1 2022 | May 11, 2022 | −$0.23 | −$0.32 | −38.11% | $0.00 | SEC |
| Q4 2021 | Mar 31, 2022 | −$0.24 | −$0.25 | −3.43% | $0.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.21 | −$0.24 | −17.07% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did PDS Biotechnology (PDSB) last report earnings?
PDS Biotechnology last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did PDSB beat earnings estimates?
No. PDS Biotechnology reported EPS of −$0.18 for Q2 2026 against a −$0.13 estimate — a 38.46% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.